Changzhou Qianhong Biopharma CO.,LTD

XSEC:002550 Stock Report

Market Cap: CN¥7.8b

Changzhou Qianhong BiopharmaLTD Past Earnings Performance

Past criteria checks 4/6

Changzhou Qianhong BiopharmaLTD has been growing earnings at an average annual rate of 16.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 3.8% per year. Changzhou Qianhong BiopharmaLTD's return on equity is 11.7%, and it has net margins of 18.9%.

Key information

16.9%

Earnings growth rate

16.2%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate3.8%
Return on equity11.7%
Net Margin18.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Changzhou Qianhong BiopharmaLTD makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:002550 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,556294358105
30 Jun 241,61324644588
31 Mar 241,66720050794
31 Dec 231,81418250297
30 Sep 232,12125351094
30 Jun 232,22324155999
31 Mar 232,36028155298
01 Jan 232,30432355688
30 Sep 222,15526066375
30 Jun 222,13929460974
31 Mar 222,03625559871
01 Jan 221,87518158871
30 Sep 211,873-8851570
30 Jun 211,886-10754669
31 Mar 211,913-5250968
31 Dec 201,668-13248869
30 Sep 201,69418848655
30 Jun 201,48715148761
31 Mar 201,45414848864
31 Dec 191,67526347665
30 Sep 191,46223249267
30 Jun 191,49023346867
31 Mar 191,35022745266
31 Dec 181,32222143667
30 Sep 181,31222241368
30 Jun 181,22320236196
31 Mar 181,16019740016
31 Dec 171,06518334564
30 Sep 1799521232449
30 Jun 179312263560
31 Mar 178632253460
31 Dec 167762243330
30 Sep 167732503240
30 Jun 167882773060
31 Mar 167502772950
31 Dec 157572672970
30 Sep 157302682700
30 Jun 157442702650
31 Mar 157712592740
31 Dec 148152452800
30 Sep 148072262440
30 Jun 147912052210
31 Mar 148321912170
31 Dec 138611872100

Quality Earnings: 002550 has high quality earnings.

Growing Profit Margin: 002550's current net profit margins (18.9%) are higher than last year (11.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002550's earnings have grown by 16.9% per year over the past 5 years.

Accelerating Growth: 002550's earnings growth over the past year (16.1%) is below its 5-year average (16.9% per year).

Earnings vs Industry: 002550 earnings growth over the past year (16.1%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 002550's Return on Equity (11.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 18:09
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Changzhou Qianhong Biopharma CO.,LTD is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peng YanChangjiang Securities Co. LTD.
Xiao Wei LinEverbright Securities Co. Ltd.
Mingrui WangEverbright Securities Co. Ltd.